We believe that glyburide and acarbose can be promising alternative therapies for the treatment of GDM. Glyburide controlled glucose levels in most patients and it was more efficient than acarbose. Glyburide showed a higher rate of macrosomia and neonatal hypoglycemia as compared to other therapies.

Weight and ponderal index were lower in the newborns of the metformin group; glucose levels (1st and 3rd h after birth) were lower in the glyburide group.

The treatment of GDM with metformin or glyburide was found to be equivalent for both women and newborns.

The pediatrician in the delivery room can expect different outcomes for diabetic mothers based on the treatment received.